Knockdown of TRIB2 inhibited hepatic stellate cells activation and liver fibrosis in vitro and in vivo [75], suggesting TRIB2 as an attractive therapeutic target for hepatic fibrosis and fibrosis-associated liver cancer. Here, TRIB2 is linked to liver cancer.